Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FORMA THERAPEUTICS HOLDINGS, INC.

(FMTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Forma Therapeutics : to Participate in Upcoming Investor Conferences

09/17/2021 | 07:06am EDT

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in two upcoming investor conferences:

- The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit taking place Sept. 20-23, 2021. Forma will present on Sept. 22, 2021 at 12:25 p.m. Eastern Time.

- The Cantor Global Healthcare Conference taking place Sept. 27-30, 2021. Forma will present on Sept. 27, 2021 at 10:40 a.m. Eastern Time.

Webcast and audio recording of the conference presentations will be available in the “News & Investors” section of Forma’s website at www.FormaTherapeutics.com.

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.


ę Business Wire 2021
All news about FORMA THERAPEUTICS HOLDINGS, INC.
10/07FORMA THERAPEUTICS : Shares Fall After it Releases Prostate Cancer Study Data
MT
10/07FORMA THERAPEUTICS : Says FT-7051 Showed Therapeutic Potential in Prostate Cancer Study
MT
10/07FORMA THERAPEUTICS' : FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in I..
PU
10/07FORMA THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Other Events (form 8-K)
AQ
10/07FORMA THERAPEUTICS : rsquo; FT-7051 is Well-tolerated and Demonstrates Evidence of Activit..
BU
10/07Forma Therapeutics Holdings, Inc. Announces Positive Initial Results from A Phase 1 Tri..
CI
09/17FORMA THERAPEUTICS : to Participate in Upcoming Investor Conferences
BU
08/17FORMA THERAPEUTICS : HC Wainwright Adjusts Price Target on Forma Therapeutics Holdings to ..
MT
08/13FORMA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/13FORMA THERAPEUTICS' : Q2 Loss Narrows, Operating Expenses Rise
MT
More news
Analyst Recommendations on FORMA THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 7,14 M - -
Net income 2021 -166 M - -
Net cash 2021 484 M - -
P/E ratio 2021 -5,27x
Yield 2021 -
Capitalization 871 M 871 M -
EV / Sales 2021 54,2x
EV / Sales 2022 175x
Nbr of Employees 139
Free-Float 92,2%
Chart FORMA THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Forma Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FORMA THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 18,40 $
Average target price 56,29 $
Spread / Average Target 206%
EPS Revisions
Managers and Directors
Frank D. Lee President, Chief Executive Officer & Director
Todd E. Shegog Chief Financial Officer & Senior Vice President
Peter Wirth Chairman
David N. Cook Chief Scientific Officer & Senior Vice President
Patrick Kelly Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
FORMA THERAPEUTICS HOLDINGS, INC.-47.39%870
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-39.69%25 455